28.03.2013 - Japanese Otsuka and Danish Lundbeck have inked a US$825m co-development and co-marketing deal in Alzheimer's disease.
Under the terms of the agreement, the Copenhagen-based neurology specialist will grant Otsuka (Tokyo) co-development and co-commercialisation rights to its selective 5-HT6-receptor antagonist LU AE58054 in the US, Canada, East Asia, Japan, and major European pharma markets.
The Japanese company will pay US$150m upfront. Both companies will share the sales, development, and commercialisation costs. Lundbeck is also entitled to up to US$675m in milestones.
A pivotal clinical programme with Lu AE58054 enroling more than 2,500 patients with mild-to-moderate Alzheimer's disease is planned to be initiated later this year. Lu AE58054 will be tested as adjunct treatment to donepezil. Last May, Lundbeck reported that Lu AE58054 had met its primary endpoint in a 24-week clinical Phase II trial in 278 patients in the same setting as the confirmatory Phase III study.
05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.
04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.
01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.
27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.
25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.
21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.